Clinical Trial Update: A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 trial of BMC128 in combination therapy evaluating a single dose level, across multiple cancers; status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• BMC128

Snippet

Sponsor: Biomica Ltd. | Conditions: Non-small Cell Lung Cancer, Melanoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING